Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Issued (2017 - 2026)

Catalyst Pharmaceuticals filings provide 15 years of Shares Issued readings, the most recent being $3.3 million for Q1 2026.

  • On a quarterly basis, Shares Issued fell 31.02% to $3.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $26.0 million, a 122.25% increase, with the full-year FY2025 number at $14.7 million, up 8.54% from a year prior.
  • Shares Issued hit $3.3 million in Q1 2026 for Catalyst Pharmaceuticals, down from $14.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $14.7 million in Q4 2025 to a low of -$127.5 million in Q4 2024.
  • Median Shares Issued over the past 5 years was $2.1 million (2024), compared with a mean of -$4.9 million.
  • Biggest five-year swings in Shares Issued: plummeted 95.0% in 2023 and later soared 1900.0% in 2024.
  • Catalyst Pharmaceuticals' Shares Issued stood at $3.2 million in 2022, then tumbled by 93.75% to $200000.0 in 2023, then tumbled by 63842.5% to -$127.5 million in 2024, then skyrocketed by 111.51% to $14.7 million in 2025, then plummeted by 77.49% to $3.3 million in 2026.
  • The last three reported values for Shares Issued were $3.3 million (Q1 2026), $14.7 million (Q4 2025), and $5.8 million (Q3 2025) per Business Quant data.